WHO Approves "Olastrocel" as International Name for Creative Medical's Lead Cell Therapy CELZ-201
核心洞察
The World Health Organization has approved "olastrocel (搜索)" as the International Non-Proprietary Name for Creative Medical Technology Holdings (搜索)' lead allogeneic cell therapy CELZ-201.
This global naming milestone provides standardized scientific identification for the therapy across regulatory jurisdictions and supports its advancement toward later-stage development.
Olastrocel (搜索) is being developed for chronic lower back pain (搜索), degenerative disc disease (搜索), type 1 diabetes (搜索), and biodefense-related indications under the company's AlloStem platform.
Creative Medical Technology Holdings (搜索) announced that the World Health Organization has approved "olastrocel (搜索)" as the International Non-Proprietary Name (INN) for the active cellular substance in CELZ-201, the company's lead allogeneic cell therapy also known as AlloStem®. This global regulatory milestone provides standardized scientific identification for the therapy as it advances through clinical development.
The INN serves as the globally standardized, unique scientific name used by regulators, clinicians, researchers, and global markets to identify a therapeutic substance throughout its development and commercialization lifecycle. This assignment typically occurs as programs advance into later regulatory stages and require unified international identification.
Strategic Significance for Global Development
"Securing the name 'olastrocel (搜索)' marks an important advancement for our program," said Timothy Warbington, President and CEO of Creative Medical. "A WHO-recognized INN is foundational for global development, medical adoption, and long-term scalability. It provides a cohesive scientific identity for the asset as we continue to execute on our clinical strategy in large markets with significant unmet medical needs."
The INN assignment provides several key advantages including globally harmonized scientific identification of the active substance, regulatory and clinical clarity across jurisdictions during development, improved efficiency in global submissions, labeling, and pharmacovigilance, and strengthened positioning in sizable therapeutic markets.
Therapeutic Applications and Market Opportunities
Olastrocel (搜索) is an allogeneic, off-the-shelf cellular therapeutic candidate derived from perinatal tissue and developed under the company's AlloStem® platform. The therapy is currently in clinical development for chronic lower back pain (搜索) and degenerative disc disease (搜索), type 1 diabetes (搜索) in new-onset cases, and biodefense-related indications.
Warbington emphasized the commercial potential, noting that "the therapeutic areas we are targeting - chronic lower back pain (搜索), diabetes, and immune-mediated conditions - represent multi-billion-dollar opportunities where innovation is urgently needed."
Regulatory Progress and Future Outlook
The WHO naming approval builds on previous regulatory achievements, including FDA Fast Track designation for degenerative disc disease (搜索). "Combined with our FDA Fast Track designation in degenerative disc disease, we believe the program is well-positioned as we move toward additional clinical catalysts ahead," Warbington stated.
The CEO described this as "an exciting moment for Creative Medical and our shareholders as we continue building a differentiated, next-generation cell therapy franchise," emphasizing the company's commitment to advancing olastrocel (搜索) through the next phases of development with a "focused, data-driven" approach.